6 completed, 3 recruiting, 1 terminated, 1 unknown. 11 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Recruiting 3, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Eye Manifestations: new trials by email Literature Review of Eye Manifestations trials Research Report on Eye Manifestations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction 150K cells, 500K cells, Placebo - Corneal Edema, Fuchs | Phase 2 | Recruiting | Emmecell | 121 | 2026-10-01 | 2026-10-09 |
| A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery Ophthalmic solution (matching formulation without ascorbic acid), Ascorbic acid ophthalmic solution 5% - Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery | Phase 2 | Recruiting | Caravel Oculus Pty Ltd | 200 | 2026-07-28 | 2026-08-06 |
| Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) SAF312 Placebo, SAF312 - Chronic Ocular Pain | Phase 2 | Completed | Novartis Pharmaceuticals | 153 | 2021-04-21 | 2024-10-09 |
| Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy Ripasudil eye drops, Optive eye drops, Descemetorhexis - Fuchs' Endothelial Dystrophy, Fuchs Dystrophy | Phase 2 | Unknown | University of Erlangen-Nürnberg Medical School | 21 | 2018-06-05 | 2018-07-12 |
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) Clemastine, Placebo - Optic Neuritis | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2017-02-28 | 2026-03-11 |
| Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery SAF312, Placebo - Postoperative Ocular Pain After PRK Surgery | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-01 | 2021-10-06 |
| Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 2 | Completed | Sylentis, S.A. | 66 | 2015-06-01 | 2016-04-05 |
| RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% - Corneal Endothelial Cell Loss, Ocular Pain | Phase 2 | Completed | Biogen | 307 | 2014-05-31 | 2025-06-03 |
| RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo - Inflammation and Pain Following Ocular Surgery | Phase 2 | Completed | Biogen | 109 | 2014-02-28 | 2025-06-03 |
| Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Sylentis, S.A. | 60 | 2012-11-01 | 2015-05-25 |
| Endothelial Cell Loss After Cataract Surgery Standard phacoemulsification, Reduced ultrasound phacoemulsification - Cataracts | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 39 | 2009-07-01 | 2014-08-25 |
Eye Pain (7) · Corneal Endothelial Cell Loss (5) · Dry Eye Syndromes (2) · Fuchs' Endothelial Dystrophy (2) · Cataract (1) · Corneal Dystrophy, Posterior Polymorphous, 1 (1) · Corneal Edema (1) · Corneal Endothelial Dystrophy 1 (1) · Corneal endothelial dystrophy type 2 (1) · Endophthalmitis (1) · Inflammation (1) · Multiple Sclerosis (1) · Optic Neuritis (1) · Vision Disorders (1)
Eye Diseases (11) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Neurologic Manifestations (7) · Pain (7) · Pathologic Processes (6) · Corneal Diseases (5) · Postoperative Complications (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Corneal Dystrophies, Hereditary (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Lacrimal Apparatus Diseases (2) · Autoimmune Diseases (1)
Ascorbic Acid (1) · Clemastine (1) · Lubricant Eye Drops (1) · Ophthalmic Solutions (1) · omaveloxolone (1)
Biogen (2) · Novartis Pharmaceuticals (2) · Sylentis, S.A. (2) · University of California, San Francisco (2) · Caravel Oculus Pty Ltd (1) · Emmecell (1) · University of Erlangen-Nürnberg Medical School (1)
United States (7) · Spain (2) · Australia (1) · Estonia (1) · Germany (1) · Japan (1) · United Kingdom (1)
Ari Green, MD, MCR (1) · David Hwang, MD (1) · Noelia Kunzevitzky, PhD (1)
2017 (1)